Category: Minimally Invasive Cardiovascular Techniques
Minimally Invasive Cardiovascular Techniques
Cardiac device maker puts the brakes on its hiring drive for a facility in Athlone, Ireland, that was to have made its Impella heart pumps.
Abiomed Inc. is putting the brakes on a hiring drive for a new manufacturing plant in Ireland to save cash, the Independent reported.
The Danvers, Mass.-based cardiac device maker is putting its plans to hire 250 workers for the plant in Athlone, Ireland, on hold because of the "tough economy," an unidentified spokeswoman told the newspaper.
Abiomed had planned for the 33,000-square-foot facility to make its Impella line of cardiac assist devices, hiring a handful of employees at the operation, including a general manager, according to the Independent.
Danvers cardiac device maker doles out bonuses and pay raises to its top executives after posting increased sales and narrowing its net losses for fiscal 2009.
Abiomed Inc. doled out bonuses and pay raises to its top executives after the Danvers-based cardiac device maker posted sales increases and narrower losses for fiscal 2009.
Boston cardiac implant maker posts $3.5 million in Q1 sales and a $3.8 million net loss as its hospital customers reduce inventory in response to the economy.
Sales and earnings continued to slide for NMT Medical Inc., as its hospital customers scaled back inventories in response to the down economy.
The Boston cardiac implant maker posted sales of $3.48 million for the three months ended March 31, down 27.9 percent compared with the same period last year.
NMT's quarterly net loss widened by 2.2 percent, reaching $3.8 million compared with $3.9 million during the first quarter of 2008.
Company officials chalked up the slide to hospitals reducing their inventories, taking longer to re-order NMT's non-invasive cardiac repair products and thereby lengthening its sales cycle.
Rockland biotech firm's HepaSphere and EmboSphere embolotherapy products will be distributed in Japan by Nippon Kayaku.
BioSphere Medical Inc. inked a deal with Nippon Kayaku Co. Ltd. to distribute two of its products in Japan.
The Rockland-based biotech firm said Nippon Kayaku will distribute its HepaSphere and Embosphere products, tiny "microspheres" used in embolotherapy procedures to treat uterine fibroids, hyper-vascularized tumors and vascular defects.
The terms of the deal call for the Japanese firm to handle and pay for the regulatory process there, "including performing any clinical studies that may be required as a condition to product registration."
Product(s):
Develops catheter-based techniques for the treatment of heart valve disease
Product(s):
Manufactures temporary cardiac assist devices
Chairman:
Michael R. Minogue
President:
Michael R. Minogue
Management:
William J. Bolt, SVP-global quality & service
Robert L. Bowen, VP, CFO
Andrew J. Greenfield, VP-healthcare solutions
Michael G. Howley, VP, GM- global sales and marketing
Robert T.V. Kung, SVP, Chief Scientific Officer
Stephen C. McEvoy, VP, general counsel
Thorsten Siess, CTO
David Weber, COO
Boston-based cardiac implant maker looks to cut costs by $1 million annually after posting dismal results for fiscal 2008.
NMT Medical Inc. has already embarked on a series of restructuring moves--including an unspecified number of layoffs--aimed at cutting its annual burn rate by $1 million.
The size and the scope of the workforce cuts, which NMT said were put in place in January, were not disclosed. NMT, which recently ousted CEO John Ahern after eight years at the helm, employs about 110 people.
Company officials announced the cost-saving moves in an earnings release March 3.
